Hyperlipidemia

Jump to navigation Jump to search

For patient information click here Template:DiseaseDisorder infobox

WikiDoc Resources for Hyperlipidemia

Articles

Most recent articles on Hyperlipidemia

Most cited articles on Hyperlipidemia

Review articles on Hyperlipidemia

Articles on Hyperlipidemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hyperlipidemia

Images of Hyperlipidemia

Photos of Hyperlipidemia

Podcasts & MP3s on Hyperlipidemia

Videos on Hyperlipidemia

Evidence Based Medicine

Cochrane Collaboration on Hyperlipidemia

Bandolier on Hyperlipidemia

TRIP on Hyperlipidemia

Clinical Trials

Ongoing Trials on Hyperlipidemia at Clinical Trials.gov

Trial results on Hyperlipidemia

Clinical Trials on Hyperlipidemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hyperlipidemia

NICE Guidance on Hyperlipidemia

NHS PRODIGY Guidance

FDA on Hyperlipidemia

CDC on Hyperlipidemia

Books

Books on Hyperlipidemia

News

Hyperlipidemia in the news

Be alerted to news on Hyperlipidemia

News trends on Hyperlipidemia

Commentary

Blogs on Hyperlipidemia

Definitions

Definitions of Hyperlipidemia

Patient Resources / Community

Patient resources on Hyperlipidemia

Discussion groups on Hyperlipidemia

Patient Handouts on Hyperlipidemia

Directions to Hospitals Treating Hyperlipidemia

Risk calculators and risk factors for Hyperlipidemia

Healthcare Provider Resources

Symptoms of Hyperlipidemia

Causes & Risk Factors for Hyperlipidemia

Diagnostic studies for Hyperlipidemia

Treatment of Hyperlipidemia

Continuing Medical Education (CME)

CME Programs on Hyperlipidemia

International

Hyperlipidemia en Espanol

Hyperlipidemia en Francais

Business

Hyperlipidemia in the Marketplace

Patents on Hyperlipidemia

Experimental / Informatics

List of terms related to Hyperlipidemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Hyperlipidemia, hyperlipoproteinemia or dyslipidemia is the presence of raised or abnormal levels of lipids and/or lipoproteins in the blood. Lipids (fatty molecules) are transported in a protein capsule, and the density of the lipids and type of protein determines the fate of the particle and its influence on metabolism.

Lipid and lipoprotein abnormalities are extremely common in the general population, and are regarded as a highly modifiable risk factor for cardiovascular disease due to the influence of cholesterol, one of the most clinically relevant lipid substances, on atherosclerosis. In addition, some forms may predispose to acute pancreatitis.

Classification

Hyperlipidemias are classified according to the Fredrickson classification which is based on the pattern of lipoproteins on electrophoresis or ultracentrifugation.[1] It was later adopted by the World Health Organization (WHO). It does not directly account for HDL, and it does not distinguish among the different genes that may be partially responsible for some of these conditions. It remains a popular system of classification, but is considered dated by many.

Fredrickson classification of Hyperlipidemias
Hyperlipoproteinemia Synonyms Problems Labs description Treatment
Type I Buerger-Gruetz syndrome, Primary hyperlipoproteinaemia, or Familial hyperchylomicronemia Decreased lipoprotein lipase (LPL) or altered ApoC2 Elevated Chylomicrons Diet Control
Type IIa Polygenic hypercholesterolaemia or Familial hypercholesterolemia LDL receptor deficiency Elevated LDL only Bile Acid Sequestrants, Statins, Niacin
Type IIb Combined hyperlipidemia Decreased LDL receptor and Increased ApoB Elevated LDL and VLDL and Triglycerides Statins, Niacin, Gemfibrozil
Type III Familial Dysbetalipoproteinemia Defect in ApoE synthesis Increased IDL Drug of choice: Gemfibrozil
Type IV Endogenous Hyperlipemia Increased VLDL production and Decreased elimination Increased VLDL Drug of choice: Niacin
Type V Familial Hypertriglyceridemia Increased VLDL production and Decreased LPL Increased VLDL and Chylomicrons Niacin, Gemfibrozil

Hyperlipoproteinemia type I

This very rare form (also known as Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or familial hyperchylomicronemia) is due to a deficiency of lipoprotein lipase (LPL) or altered apolipoprotein C2, resulting in elevated chylomicrons, the particles that transfer fatty acids from the digestive tract to the liver. Lipoprotein lipase is also responsible for the initial breakdown of endogenously made triacylglycerides in the form of very low density lipoprotein (VLDL). As such, one would expect a defect in LPL to also result in elevated VLDL. Its prevalence is 0.1% of the population.

Hyperlipoproteinemia type II

Hyperlipoproteinemia type II, by far the most common form, is further classified into type IIa and type IIb, depending mainly on whether there is elevation in the triglyceride level in addition to LDL cholesterol.

Type IIa

This may be sporadic (due to dietary factors), polygenic, or truly familial as a result of a mutation either in the LDL receptor gene on chromosome 19 (0.2% of the population) or the ApoB gene (0.2%). The familial form is characterized by tendon xanthoma, xanthelasma and premature cardiovascular disease.

Type IIb

The high VLDL levels are due to overproduction of substrates, including triglycerides, acetyl CoA, and an increase in B-100 synthesis. They may also be caused by the decreased clearance of LDL. Prevalence in the population is 10%.

  • Familial combined hyperlipoproteinemia (FCH)
  • Secondary combined hyperlipoproteinemia (usually in the context of metabolic syndrome, for which it is a diagnostic criterion)

Treatment

While dietary modification is the initial approach, many patients require treatment with statins (HMG-CoA reductase inhibitors) to reduce cardiovascular risk. If the triglyceride level is markedly raised, fibrates may be preferable due to their beneficial effects. Combination treatment of statins and fibrates, while highly effective, causes a markedly increased risk of myopathy and rhabdomyolysis and is therefore only done under close supervision. Other agents commonly added to statins are ezetimibe, niacin and bile acid sequestrants. There is some evidence for benefit of plant sterol-containing products and ω3-fatty acids[2]

Hyperlipoproteinemia type III

This form is due to high chylomicrons and IDL (intermediate density lipoprotein). Also known as broad beta disease or dysbetalipoproteinemia, the most common cause for this form is the presence of ApoE E2/E2 genotype. It is due to cholesterol-rich VLDL (β-VLDL). Prevalence is 0.02% of the population.

Hyperlipoproteinemia type IV

This form is due to high triglycerides. It is also known as hypertriglyceridemia (or pure hypertriglyceridemia). According to the NCEP-ATPIII definition of high triglycerides (>200 mg/dl), prevalence is about 16% of adult population.[3]

Hyperlipoproteinemia type V

This type is very similar to type I, but with high VLDL in addition to chylomicrons.

It is also associated with glucose intolerance and hyperuricemia

Unclassified forms

Non-classified forms are extremely rare:

  • Hypo-alpha lipoproteinemia
  • Hypo-beta lipoproteinemia (prevalence 0.01-0.1%)

References

  1. Frederickson DS, Lee RS. A system for phenotyping hyperlipidemia. Circulation 1965;31:321-7. PMID 14262568.
  2. Thompson GR. Management of dyslipidaemia. Heart 2004;90:949-55. PMID 15253984.
  3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106; page 3240

External links

Hyperlipoproteinemia OMIM GPnotebook WebMD Others
Type I Online Mendelian Inheritance in Man (OMIM) 238600 Template:GPnotebook . MeritCare
Type IIa Online Mendelian Inheritance in Man (OMIM) 144400 Template:GPnotebook . Merck
Type IIb Template:GPnotebook .
Type III . Template:GPnotebook WebMD Yahoo
Type IV Online Mendelian Inheritance in Man (OMIM) 144600 Template:GPnotebook WebMD Yahoo
Type V Online Mendelian Inheritance in Man (OMIM) 144600 Template:GPnotebook . .

Template:Metabolic pathology Template:SIB

de:Hyperlipoproteinämie he:היפרליפידמיה sv:Hyperlipidemi


Template:WikiDoc Sources